is this you? Claim your profile.
is this you? Claim your profile.
Head of Science Funding
HQ Phone:  +44 20 7611 8888
Direct Phone: +44 ** **** ****
+ Get 10 Free Contacts a Month
It's free and takes 30 seconds
Wellcome Trust 210 Euston Road
London, Greater London,NW1 2BE
The Wellcome Trust is the second-highest-spending global charitable foundation, dedicated to achieving extraordinary improvements in human and animal health. It supports bright minds in biomedical research and the medical humanities, including public engagemen... more.
Chief Executive Officer
Academic Publishing Platforms
Advisory Board Member
Population Genetics Technologies Ltd
Structural Genomics Consortium
University of Toronto
Department of Genetics
Senior Post-doctoral Fellow
Bachelor of Business Administration degree
University of Iowa
Fred Hutchinson Cancer Research Center
Ӣ������ҽѧ����רҵ(Biomedical Science)�Ƽ���ѧ | Ӣ��ѧ�ӽ��� (SUUK)
(Wellcome Trust)û7.5ûŸ(Alan Schafer)ÿ ûü¥á
14M Genomics appoints Alan Schafer as Chief Executive Officer
14th July 2015 14M Genomics, a developer of cancer clinical diagnostic and treatment decision tools, announced today the appointment of Alan Schafer, PhD to the post of Chief Executive Officer. Dr. Schafer brings extensive experience in research, in big pharma and biotechnology management, as well as in building new businesses. Alan previously served as CEO of Population Genetics Technologies where he led the development and commercialisation strategy for next generation sequencing based diagnostic products to inform clinical decision-making in infectious disease. Prior to this, Alan served as the Wellcome Trust's Director of Science Funding and was previously Global Vice-President of Technology Development at GlaxoSmithKline. Alan was a co-founder of Hexagen, a functional genomics company that was acquired by Incyte where he subsequently served as Vice President of Genetics. He has also provided advisory and consultancy services to investment and biotechnology firms. "We are delighted to have Alan lead our development and commercialisation of clinical genomics diagnostic and treatment decision support services in cancer," said Andrew Sandham, Executive Chairman of 14M Genomics. Commenting on his appointment as CEO, Alan Schafer added: "I am devoted to excellence in research and its application to improve the diagnosis and treatment of cancer patients. 14M Genomics appoints Alan Schafer as Chief Executive Officer 14th July 2015 14M Genomics, a developer of cancer clinical diagnostic and treatment decision tools, announced today the appointment of Alan Schafer, PhD to...
Alan Schafer named CEO of 14M Genomics
Tuesday 14 July 2015 Company: 14M Genomics Ltd Appointee: Alan Schafer 14M Genomics Ltd, a cancer diagnostics company, has appointed Alan Schafer as its chief executive officer. Dr Schafer was previously CEO of Population Genetics Technologies Inc in the US where he led that company's commercialisation strategy for next generation sequencing-based diagnostic products for infectious disease. Prior to that, he was director of science funding for the Wellcome Trust. Alan Schafer named CEO of 14M Genomics
Dr Alan Schafer, Chief Executive Officer, 14M Genomics
14M Genomics and EORTC and Announce First Results from their Collaboration on Tumour Profiling | EORTC
Alan Schafer, Chief Executive of 14MG, said, "We are delighted to announce delivery of the first patient tumour genomic profiles in our collaboration with the EORTC, its clinical centres and investigators.